PROM1/CD133 marks a proliferative stem cell-like population of blasts in KMT2A rearranged infant ALL.

IF 7.1 1区医学 Q1 HEMATOLOGY

Blood advances Pub Date : 2025-09-23 DOI:10.1182/bloodadvances.2024015185

Joe Wilson Cross, Lucy Field, Alastair Smith, Emily Neil, Lucy Hamer, Thomas Jackson, Natalina Elliott, Siobhan Rice, Nicholas Crump, Joe Harman, Rebecca E Ling, Qingqing Wu, Nouhad El Ouazzani, Rebecca Thomas, Sarah Inglott, Jack Bartram, Owen Smith, Jonathan Bond, Irene Roberts, Thomas A Milne, Anindita Roy

引用次数: 0

查看原文本刊更多论文

Prom1 / cd133标志着kmt2a重排婴儿细胞的增殖干细胞样细胞群。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood advances Medicine-Hematology

CiteScore

12.70

自引率

2.70%

发文量

840

期刊介绍： Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.